KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer
ConclusionWe conclude that KMT2C could serve as a potential biomarker of prognosis and chemotherapy sensitivity by affecting the DNA damage repair-related genes of breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Gastroschisis Repair | Genetics